Predicting disease progression in high-grade glioma with neuropsychological parameters: The value of personalized longitudinal assessment

Elke Butterbrod*, J. Bruijn, Meriam Braaksma, Geert-Jan Rutten, Cees Tijssen, Monique Hanse, Margriet Sitskoorn, Karin Gehring

*Corresponding author for this work

Research output: Contribution to journalArticleScientificpeer-review

12 Downloads (Pure)

Abstract

Purpose: 
Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.
Methods: 
Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.
Results: 
Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.
Conclusions: 
Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.
Original languageEnglish
Pages (from-to)511-518
JournalJournal of Neuro-Oncology
Volume144
Issue number3
DOIs
Publication statusPublished - 2019

Fingerprint

Glioma
Ambulatory Surgical Procedures
Proportional Hazards Models
Cognitive Dysfunction

Keywords

  • COGNITIVE FUNCTION
  • Cognitive functioning
  • DISORDERS
  • Disease progression
  • GLIOBLASTOMA
  • High-grade glioma
  • Neuropsychological assessment
  • RANO
  • SURVIVAL
  • TUMOR

Cite this

@article{2d55018198d84c858bab225bda5e518d,
title = "Predicting disease progression in high-grade glioma with neuropsychological parameters:: The value of personalized longitudinal assessment",
abstract = "Purpose: Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.Methods: Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.Results: Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60{\%}). Decline was absent in 8/10 patients (80{\%}) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.Conclusions: Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.",
keywords = "COGNITIVE FUNCTION, Cognitive functioning, DISORDERS, Disease progression, GLIOBLASTOMA, High-grade glioma, Neuropsychological assessment, RANO, SURVIVAL, TUMOR",
author = "Elke Butterbrod and J. Bruijn and Meriam Braaksma and Geert-Jan Rutten and Cees Tijssen and Monique Hanse and Margriet Sitskoorn and Karin Gehring",
year = "2019",
doi = "10.1007/s11060-019-03249-1",
language = "English",
volume = "144",
pages = "511--518",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Predicting disease progression in high-grade glioma with neuropsychological parameters: The value of personalized longitudinal assessment. / Butterbrod, Elke; Bruijn, J.; Braaksma, Meriam; Rutten, Geert-Jan; Tijssen, Cees ; Hanse, Monique; Sitskoorn, Margriet; Gehring, Karin.

In: Journal of Neuro-Oncology, Vol. 144, No. 3, 2019, p. 511-518.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - Predicting disease progression in high-grade glioma with neuropsychological parameters:

T2 - The value of personalized longitudinal assessment

AU - Butterbrod, Elke

AU - Bruijn, J.

AU - Braaksma, Meriam

AU - Rutten, Geert-Jan

AU - Tijssen, Cees

AU - Hanse, Monique

AU - Sitskoorn, Margriet

AU - Gehring, Karin

PY - 2019

Y1 - 2019

N2 - Purpose: Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.Methods: Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.Results: Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.Conclusions: Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.

AB - Purpose: Progressive disease in patients with high-grade glioma may be reflected in cognitive decline. However, the cognitive functions most sensitive to progression may differ between patients. We investigated whether decline on a personalized selection of tests predicted progressive disease according to RANO criteria in high-grade glioma patients.Methods: Starting one day before surgery, patients underwent neuropsychological assessment every three months during standard treatment and clinical follow-up. We first made a personalized selection of three tests that showed the highest Reliable Change Index (RCI) values, i.e., most positive change, at the first post-surgical assessment for each patient. In subsequent follow up, a decline of RCI ≤ − 1 on at least two of the three tests in the selection was considered cognitive decline. We performed a discrete Cox proportional hazards model including a time-dependent coefficient cognitive decline (vs. stability) and covariate age to predict progressive disease.Results: Twenty five patients were included. Cognitive decline on the personalized test selection preceded or had occurred by the time progression was established in 9/15 patients with RANO confirmed progressive disease (60%). Decline was absent in 8/10 patients (80%) with stable disease during participation. The independent hazard ratio for progression in case of cognitive decline was 5.05 (p < 0.01) compared to stable performance.Conclusions: Using only three patient-specific neuropsychological tests, we found a fivefold increased chance of disease progression in case of cognitive decline as compared to stable performance. Brief, patient-tailored cognitive assessment may be a noninvasive addition to disease monitoring without overburdening patients and clinical care.

KW - COGNITIVE FUNCTION

KW - Cognitive functioning

KW - DISORDERS

KW - Disease progression

KW - GLIOBLASTOMA

KW - High-grade glioma

KW - Neuropsychological assessment

KW - RANO

KW - SURVIVAL

KW - TUMOR

U2 - 10.1007/s11060-019-03249-1

DO - 10.1007/s11060-019-03249-1

M3 - Article

C2 - 31342318

VL - 144

SP - 511

EP - 518

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -